How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

3,313 results for

Myocardial Infarction Stabilization

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

101. The relationship of MicroRNA-21 and plaque stability in acute coronary syndrome. Full Text available with Trip Pro

The relationship of MicroRNA-21 and plaque stability in acute coronary syndrome. Acute coronary syndrome (ACS) leads to clinical symptoms such as chest pain, dyspnea, and arrhythmia. The occurrence of ACS is mainly related to the vulnerable plaques in the coronary arteries. MicroRNA-21 (miR-21) is widely expressed in cardiovascular disease and considered as a marker of myocardial infarction, but its role in vulnerable atherosclerotic plaque of ACS is poorly studied. The cases of ACS and control

2019 Medicine

102. Multiparametric CMR Imaging of Infarct Remodeling in a Percutaneous Reperfused Yucatan Mini-pig Model Full Text available with Trip Pro

mass on Day 2), which led to significant adverse myocardial remodeling that stabilized beyond 30 days. Native T1 values did not reliably differentiate remote and infarct regions acutely. There was no evidence of remote fibrosis as indicated by partition coefficient and collagen fraction analyses. The infarct T2 values remained elevated up to 60 days after MI. Multiparametric CMR in this model showed significant adverse ventricular remodeling 30 days after MI similar to that seen in humans (...) Multiparametric CMR Imaging of Infarct Remodeling in a Percutaneous Reperfused Yucatan Mini-pig Model To further understanding of the temporal evolution and pathophysiology of adverse ventricular remodeling over the first 60 days following a myocardial infarction (MI) in both the infarcted and remote myocardium, we performed multi-parametric cardiac magnetic resonance (CMR) imaging in a closed-chest chronic Yucatan mini-pig model of reperfused MI. Ten animals underwent 90 min left anterior

2017 NMR in Biomedicine

103. A Single Injection of Protein-loaded Coacervate-Gel Significantly Improves Cardiac Function Post Infarction Full Text available with Trip Pro

A Single Injection of Protein-loaded Coacervate-Gel Significantly Improves Cardiac Function Post Infarction After myocardial infarction (MI), the heart undergoes fibrotic pathological remodeling instead of repair and regeneration. With multiple pathologies developing after MI, treatment using several proteins is expected to address this range of pathologies more effectively than a single-agent therapy. A factorial design of experiments study guided us to combine three complementary factors (...) in one injection: tissue inhibitor of metalloproteinases-3 (TIMP-3) was embedded in a fibrin gel for signaling in the initial phase of the treatment, while basic fibroblast growth factor (FGF-2) and stromal cell-derived factor 1-alpha (SDF-1α) were embedded in heparin-based coacervates for sustained release and distributed within the same fibrin gel to exert their effects over a longer period. The gel was then tested in a rat model of myocardial infarction. Contractility of rat hearts treated

2017 Biomaterials

104. Myocardial Edema, Myocyte Injury, and Disease Severity in Fabry Disease. Full Text available with Trip Pro

associations in FD. Methods A prospective international multicenter study was conducted on 186 consecutive FD patients (45.2±1.1 years, 58% females). Additionally, 28 patients with hypertrophic cardiomyopathy, 30 with chronic myocardial infarction and 59 healthy volunteers were included. All study participants underwent comprehensive cardiovascular magnetic resonance with T1 and T2 mapping, cines, and LGE imaging. Results LGE in the basal inferolateral wall in FD had T2 elevation (FD 58.2±5.0 ms versus (...) hypertrophic cardiomyopathy 55.6±4.3 ms, chronic myocardial infarction 53.7±3.4 ms and healthy volunteers 48.9±2.5 ms, P<0.001), but when LGE was present there was also global T2 elevation (53.1±2.9 versus 50.6±2.2 ms, P<0.001). Thirty-eight percent of FD patients had high troponin. The strongest predictor of increased troponin was high basal inferolateral wall T2 (odds ratio, 18.2 [95% CI, 3.7-90.9], P<0.0001). Both T2 and troponin elevations were chronic over 1 year. High basal inferolateral wall T2

2020 Circulation. Cardiovascular imaging

105. The effect of rivaroxaban on myocardial infarction in the ATLAS ACS 2 - TIMI 51 trial. (Abstract)

The effect of rivaroxaban on myocardial infarction in the ATLAS ACS 2 - TIMI 51 trial. Rivaroxaban reduces cardiovascular death, myocardial infarction (MI), or stroke in patients following acute coronary syndrome (ACS). We aimed to characterize the specific effects of rivaroxaban on the size and type of MI.The Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary Syndrome-Thrombolysis in Myocardial Infarction 51 (ATLAS ACS 2-TIMI 51 (...) , p=0.04).In patients stabilized and followed after ACS, the majority of MIs that occur are spontaneous and rivaroxaban significantly reduced the incidence of these events. Notably, rivaroxaban reduced MIs with extensive biomarker release and ST-segment elevation.© The European Society of Cardiology 2014.

2014 European heart journal. Acute cardiovascular care Controlled trial quality: uncertain

106. Administration of a Synthetic Peptide Derived from the E-domain Region of Mechano-Growth Factor Delays Decompensation Following Myocardial Infarction Full Text available with Trip Pro

Administration of a Synthetic Peptide Derived from the E-domain Region of Mechano-Growth Factor Delays Decompensation Following Myocardial Infarction Insulin like growth factor-I (IGF-1) isoforms differ structurally in their E-domain regions and their temporal expression profile in response to injury. We and others have reported that Mechano-growth factor (MGF), which is equivalent to human IGF-1c and rodent IGF-1Eb isoforms, is expressed acutely following myocardial infarction (MI (...) ) in the mouse heart. To examine the function of the E-domain region, we have used a stabilized synthetic peptide analog corresponding to the unique 24 amino acid region E-domain of MGF. Here we deliver the human MGF E-domain peptide to mice during the acute phase (within 12 hours) and the chronic phase (8 weeks) post-MI. We assessed the impact of peptide delivery on cardiac function and cardiovascular hemodynamics by pressure-volume (P-V) loop analysis and gene expression by quantitative RT-PCR

2014 International journal of cardiovascular research

107. β-blockers and cardiovascular events in patients with and without myocardial infarction: post hoc analysis from the CHARISMA trial. Full Text available with Trip Pro

β-blockers and cardiovascular events in patients with and without myocardial infarction: post hoc analysis from the CHARISMA trial. The long-term efficacy of β-blockers in patients with and without myocardial infarction (MI) is controversial.This is post hoc analysis from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial of 4772 patients with prior MI, 7804 patients with known atherothrombosis, and 2101 patients with risk

2014 Circulation. Cardiovascular quality and outcomes Controlled trial quality: predicted high

108. Characterization of cardiovascular clinical events and impact of event adjudication on the treatment effect of darapladib versus placebo in patients with stable coronary heart disease: Insights from the STABILITY trial. Full Text available with Trip Pro

disease.Investigators were instructed to report all potential events. Each reported event was reviewed independently by 2 reviewers according to prespecified processes and prespecified end point definitions. Concordance between reported and adjudicated cardiovascular (CV) events was evaluated, as well as event classification influence on final study results.In total, CEC reviewed 7,096 events: 1,064 deaths (696 CV deaths), 958 myocardial infarctions (MI), 433 strokes, 182 transient ischemic attacks, 2,052 coronary (...) Characterization of cardiovascular clinical events and impact of event adjudication on the treatment effect of darapladib versus placebo in patients with stable coronary heart disease: Insights from the STABILITY trial. Clinical Endpoint Classification (CEC) in clinical trials allows FOR standardized, systematic, blinded, and unbiased adjudication of investigator-reported events. We quantified the agreement rates in the STABILITY trial on 15,828 patients with stable coronary heart

2018 American Heart Journal

109. Delivery of progenitor cells with injectable shear-thinning hydrogel maintains geometry and normalizes strain to stabilize cardiac function after ischemia. (Abstract)

Delivery of progenitor cells with injectable shear-thinning hydrogel maintains geometry and normalizes strain to stabilize cardiac function after ischemia. The ventricle undergoes adverse remodeling after myocardial infarction, resulting in abnormal biomechanics and decreased function. We hypothesize that tissue-engineered therapy could minimize postischemic remodeling through mechanical stress reduction and retention of tensile myocardial properties due to improved endothelial progenitor cell (...) retention and intrinsic biomechanical properties of the hyaluronic acid shear-thinning gel.Endothelial progenitor cells were harvested from adult Wistar rats and resuspended in shear-thinning gel. The constructs were injected at the border zone of ischemic rat myocardium in an acute model of myocardial infarction. Myocardial remodeling, tensile properties, and hemodynamic function were analyzed: control (phosphate-buffered saline), endothelial progenitor cells, shear-thinning gel, and shear-thinning gel

2018 Journal of Thoracic and Cardiovascular Surgery

110. HuR-mediated SCN5A mRNA stability reduces arrhythmic risk in heart failure. Full Text available with Trip Pro

in HF.Quantitative real-time reverse-transcriptase polymerase chain reaction was used to investigate the expression of SCN5A. Optical mapping of the intact heart was adopted to study the effects of HuR on the conduction velocity and action potential upstroke in mice with myocardial infarct and HF after injection of AAV9 viral particles carrying HuR.HuR was associated with SCN5A mRNA in cardiomyocytes, and expression of HuR was downregulated in failing hearts. The association of HuR and SCN5A mRNA protected SCN5A (...) HuR-mediated SCN5A mRNA stability reduces arrhythmic risk in heart failure. Downregulated sodium currents in heart failure (HF) have been linked to increased arrhythmic risk. Reduced expression of the messenger RNA (mRNA)-stabilizing protein HuR (also known as ELAVL1) may be responsible for the downregulation of sodium channel gene SCN5A mRNA.The purpose of this article was to investigate whether HuR regulates SCN5A mRNA expression and whether manipulation of HuR benefits arrhythmia control

2018 Heart Rhythm

111. FAT10 attenuates hypoxia-induced cardiomyocyte apoptosis by stabilizing caveolin-3. (Abstract)

myocardial tissues and in hypoxic cardiomyocytes. Furthermore, our results demonstrated that FAT10 inhibits hypoxia-induced cardiomyocyte apoptosis by increasing Cav-3 expression. Importantly, following myocardial infarction, knockout of FAT10 aggravated cardiac dysfunction and increased cardiomyocyte apoptosis by reducing Cav-3 expression. Additionally, Cav-3 was degraded by the ubiquitin-proteasome system (UPS) in cardiomyocytes. Mechanistically, we found that FAT10 stabilizes Cav-3 expression (...) FAT10 attenuates hypoxia-induced cardiomyocyte apoptosis by stabilizing caveolin-3. FAT10, a member of the ubiquitin-like-modifier family of proteins, plays a cardioprotective role in response to hypoxic/ischemic injury. Caveolin-3 (Cav-3), a muscle-specific caveolin family member, is involved in cardiomyocyte apoptosis. However, the link between FAT10 and Cav-3 in ischemic cardiomyocytes is unclear. In the present study, we found that both FAT10 and Cav-3 were upregulated in ischemic

2018 Journal of Molecular and Cellular Cardiology

112. Study on STEMI Reperfusion Strategy Based on the Characterization of Criminal Lesions Stability

of endovascular imaging in STEMI emergency intervention strategies. Condition or disease Intervention/treatment ST Elevation Myocardial Infarction Device: optical coherence tomography Detailed Description: This study is a prospective, randomized, controlled multicenter clinical study. Twenty hundred and forty AMI patients (according to all the inclusion criteria and did not meet any exclusion criteria) who were enrolled in the culprit who had a lesion stenosis ≤70% and who had TIMI blood flow grade 3 (...) of recurrent myocardial ischemic events (angina pectoris and recurrent myocardium, infarction) or sudden death within 1 month after discharge. [ Time Frame: 1 month ] the incidence of recurrent myocardial ischemic events (angina pectoris and recurrent myocardium, infarction) or sudden death within 1 month after discharge. Secondary Outcome Measures : HF incidence [ Time Frame: 1 year ] HF incidence Stent patency and stenosis rate [ Time Frame: 1 year ] Stent patency and stenosis rate Incidence

2018 Clinical Trials

113. NRX100 vs. Placebo for Rapid Stabilization of Acute Suicidal Ideation and Behavior in Bipolar Depression

to missing medication dose/s this is not exclusionary. Hypertension, Stage 2, as defined by a systolic blood pressure ≥155 mmHg or diastolic blood pressure ≥99 mmHg within 1.5 hours prior to ketamine infusion on two of three measurements at least 15 minutes apart at the pre-ketamine assessment (on Day 0 at Visit 1). Recent myocardial infarction (within one year). Syncopal event within the past year. Congestive heart failure (CHF) New York Heart Association Criteria >Stage 2. Angina pectoris. Heart rate (...) NRX100 vs. Placebo for Rapid Stabilization of Acute Suicidal Ideation and Behavior in Bipolar Depression NRX100 vs. Placebo for Rapid Stabilization of Acute Suicidal Ideation and Behavior in Bipolar Depression - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100

2018 Clinical Trials

114. A Clinical Study to Evaluate the Bioavailability Between Two Products Containing Paliperidone 100 mg in the Form of a Prolonged Release Suspension for Injection in Patients With Schizophrenia Who Are Already Stabilized in This Treatment

has positive test for illicit drugs or alcohol before any dose. The patient is suffering from severe hepatic impairment. The patient is suffering from renal impairment Presence or history of clinically significant cardiovascular disease (especially known history of QT prolongation, congenital long QT syndrome, recent acute myocardial infarction, cardiac arrhythmias, or with uncompensated heart failure). The patient is receiving medicinal products known to prolong the QT interval, e.g. class 1 (...) A Clinical Study to Evaluate the Bioavailability Between Two Products Containing Paliperidone 100 mg in the Form of a Prolonged Release Suspension for Injection in Patients With Schizophrenia Who Are Already Stabilized in This Treatment A Clinical Study to Evaluate the Bioavailability Between Two Products Containing Paliperidone 100 mg in the Form of a Prolonged Release Suspension for Injection in Patients With Schizophrenia Who Are Already Stabilized in This Treatment - Full Text View

2018 Clinical Trials

115. Myocardial Infarction (Diagnosis)

Myocardial Infarction (Diagnosis) Myocardial Infarction: Practice Essentials, Background, Definitions Edition: No Results No Results Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. https://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache=aHR0cHM6Ly9lbWVkaWNpbmUubWVkc2NhcGUuY29tL2FydGljbGUvMTU1OTE5LW92ZXJ2aWV3 processing > Myocardial Infarction Updated (...) : Jul 19, 2018 Author: A Maziar Zafari, MD, PhD; Chief Editor: Eric H Yang, MD Share Email Print Feedback Close Sections Sections Myocardial Infarction Overview Practice Essentials Myocardial infarction (MI) (ie, heart attack) is the irreversible death (necrosis) of heart muscle secondary to prolonged lack of oxygen supply (ischemia). Approximately 1.5 million cases of MI occur annually in the United States. See the images below. Acute myocardial infarction, reperfusion type. In this case

2014 eMedicine.com

116. Complications of Myocardial Infarction (Treatment)

Complications of Myocardial Infarction (Treatment) Complications of Myocardial Infarction: Overview, Arrhythmic Complications of MI, Arrhythmic Complications: Supraventricular Tachyarrhythmias Edition: No Results No Results Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. https://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache (...) =aHR0cHM6Ly9lbWVkaWNpbmUubWVkc2NhcGUuY29tL2FydGljbGUvMTY0OTI0LW92ZXJ2aWV3 processing > Complications of Myocardial Infarction Updated: Dec 18, 2014 Author: Ashok K Kondur, MD; Chief Editor: Eric H Yang, MD Share Email Print Feedback Close Sections Sections Complications of Myocardial Infarction Overview Overview Myocardial infarction (MI) due to coronary artery disease is a leading cause of death in the United States, where more than 1 million people have acute myocardial infarctions (AMIs) each year. [ ] The advent of coronary care units and early reperfusion

2014 eMedicine.com

117. Myocardial Infarction (Treatment)

adjunctive use of GP II b /III a inhibitors is not recommended but may be considered in selected cases. [ , ] Previous Next: Non-ST-Elevation (NSTE) ACS Key points in the management of patients with non–ST-elevation acute coronary syndrome (NSTE-ACS) (unstable angina and non-STE myocardial infarction [NSTEMI]) is early evaluation and assessment of hemodynamic and electrical stability, estimatation of the overall risk in these patients, and guidance of therapy. There are two alternative management (...) or bivalirudin), as fondaparinux is associated with a higher risk of catheter thrombosis; this was demonstrated in the Fifth Organization to Assess Strategies in Ischemic Syndromes (OASIS-5) trial. [ , , ] Previous Next: Additional Aspects of Management and Late Hospital Care After the initial management and stabilization of the patient in the early and critical phase of acute myocardial infarction (MI), the goals of care for these patients is to restore normal activities, prevent long-term complications

2014 eMedicine.com

118. Complications of Myocardial Infarction (Overview)

Complications of Myocardial Infarction (Overview) Complications of Myocardial Infarction: Overview, Arrhythmic Complications of MI, Arrhythmic Complications: Supraventricular Tachyarrhythmias Edition: No Results No Results Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. https://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache (...) =aHR0cHM6Ly9lbWVkaWNpbmUubWVkc2NhcGUuY29tL2FydGljbGUvMTY0OTI0LW92ZXJ2aWV3 processing > Complications of Myocardial Infarction Updated: Dec 18, 2014 Author: Ashok K Kondur, MD; Chief Editor: Eric H Yang, MD Share Email Print Feedback Close Sections Sections Complications of Myocardial Infarction Overview Overview Myocardial infarction (MI) due to coronary artery disease is a leading cause of death in the United States, where more than 1 million people have acute myocardial infarctions (AMIs) each year. [ ] The advent of coronary care units and early reperfusion

2014 eMedicine.com

119. Myocardial Infarction (Overview)

Myocardial Infarction (Overview) Myocardial Infarction: Practice Essentials, Background, Definitions Edition: No Results No Results Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. https://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache=aHR0cHM6Ly9lbWVkaWNpbmUubWVkc2NhcGUuY29tL2FydGljbGUvMTU1OTE5LW92ZXJ2aWV3 processing > Myocardial Infarction Updated (...) : Jul 19, 2018 Author: A Maziar Zafari, MD, PhD; Chief Editor: Eric H Yang, MD Share Email Print Feedback Close Sections Sections Myocardial Infarction Overview Practice Essentials Myocardial infarction (MI) (ie, heart attack) is the irreversible death (necrosis) of heart muscle secondary to prolonged lack of oxygen supply (ischemia). Approximately 1.5 million cases of MI occur annually in the United States. See the images below. Acute myocardial infarction, reperfusion type. In this case

2014 eMedicine.com

120. Myocardial Infarction (Follow-up)

adjunctive use of GP II b /III a inhibitors is not recommended but may be considered in selected cases. [ , ] Previous Next: Non-ST-Elevation (NSTE) ACS Key points in the management of patients with non–ST-elevation acute coronary syndrome (NSTE-ACS) (unstable angina and non-STE myocardial infarction [NSTEMI]) is early evaluation and assessment of hemodynamic and electrical stability, estimatation of the overall risk in these patients, and guidance of therapy. There are two alternative management (...) or bivalirudin), as fondaparinux is associated with a higher risk of catheter thrombosis; this was demonstrated in the Fifth Organization to Assess Strategies in Ischemic Syndromes (OASIS-5) trial. [ , , ] Previous Next: Additional Aspects of Management and Late Hospital Care After the initial management and stabilization of the patient in the early and critical phase of acute myocardial infarction (MI), the goals of care for these patients is to restore normal activities, prevent long-term complications

2014 eMedicine.com

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>